23 September, 2015 – C4X Discovery Holdings plc (“C4XD”), a leader in rational drug discovery and design, is pleased to provide the following research update on recent key milestones in its programmes for Type 2 diabetes and inflammation, two areas of significant unmet medical need that represent large pharmaceutical markets.
3 September, 2015 – C4X Discovery Holdings plc (“C4XD” or “the Company”), a leader in rational drug discovery and design, today announced that it is further strengthening its team with two new management appointments.
20 May, 2015 – C4X Discovery Holdings plc ("C4XD" or "the Company"), a leader in rational drug discovery and design, today announced that it has selected a drug candidate from its Orexin-1 programme to enter pre-clinical development prior to the initiation of clinical studies for the treatment of stress-related addictive disorders. This represents a major milestone for C4XD.
Manchester and London, UK, 27 April, 2015 – C4X Discovery Holdings plc (AIM: C4XD), a leader in the rational discovery design and optimisation of novel small molecule therapeutics, today announces its interim unaudited results for the six months ended 31 January 2015.
Manchester and London, UK, 30 March, 2015 – C4X Discovery (AIM: C4XD), a leader in rational drug discovery and design, today announced that it has won a further grant from the UK's innovation agency, Innovate UK. This Smart award is the second Innovate UK grant C4XD has won recently in the area of type 2 diabetes, following our success with the Biomedical Catalyst, announced in July 2014.
Manchester and London, UK, 19 January, 2015 – C4X Discovery Holdings plc (C4XD), a leader in rational drug discovery and design, announced today that it has entered into a research agreement with Evotec. Under the agreement C4XD's proprietary NMR-based technology and conformational design expertise will combine with Evotec's extensive biology and chemistry expertise. The aim is to develop several series of Orexin-1 selective inhibitors, building on elements of the substantial work which C4XD has previously conducted in the field of specific Orexin inhibitors.
Manchester and London, UK, 18 December, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, announced today that it has extended its research collaboration agreement with Evotec, under which C4XD's proprietary NMR-based technology and conformational design expertise is applied across a number of Evotec's pre-clinical therapeutic projects to enhance lead discovery and hit identification.
Manchester and London, UK, 23 October, 2014 – C4X Discovery (C4XD), a drug development company with a leading technology for rational drug discovery and design, announced that Admission and trading of its Ordinary Shares commences today on the AIM market of the London Stock Exchange ('AIM').
